Trials / Completed
CompletedNCT02912260
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients With Non-alcoholic Steatohepatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 125 (actual)
- Sponsor
- Madrigal Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in participants with biopsy-proven Non-alcoholic Steatohepatitis (NASH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MGL-3196 | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-10-18
- Primary completion
- 2017-10-25
- Completion
- 2021-11-23
- First posted
- 2016-09-23
- Last updated
- 2025-12-23
- Results posted
- 2025-12-23
Locations
26 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02912260. Inclusion in this directory is not an endorsement.